Australia's most trusted source of pharma news
Thursday, 02 October 2014
Lost Your Access?
PBS savings $14bn by 2020: Guild
Savings from PBS reforms could total nearly $14 billion between 2015 and 2020 - and that is being conservative, says Pharmacy Guild executive director David Quilty.
Eisai makes PBS debut with Halaven
Japanese giant Eisai has seen its first drug debut on the PBS in the form of breast cancer treatment
TGA warns on safety of four drugs
Four molecules have been targeted by the TGA for safety warnings in its latest update: bupropion, methylphenidate, propranolol and valproate.
Sanofi lumped with Arava court costs
Sanofi has been ordered to pay a majority of the costs related to its court battle it with Apotex over rheumatoid arthritis treatments
New evidence backs Zytiga extension
Trial results presented at the European Society for Medical Oncology Congress this week give backing to Janssen's case for PBS extension of prostate cancer drug
to patients with advanced disease.
TGA checks Xolair label changes
The FDA has announced label changes for Novartis' asthma drug
that include increased risk of problems involving heart and brain blood vessels and the TGA is tuning in.
Global cancer patent case hits Aust
A global patent battle between BMS and MSD over use of the next big thing in drugs for cancer has arrived in Australia with MSD first to hit the warpath.
SPD cuts 'devastating' generics
As PBS price cuts worth a projected $500 million take effect today, the GMiA is warning of their devastating effects on the sector that supplies the majority of PBS scripts.
MA goes back to ACCC again
More than two months after submissions to the ACCC officially closed, the industry peak body has made a further submission, responding to Health Department claims.
Champix label toned down
Pfizer has passed on to the TGA details of US changes to its
label that include data showing no increase in suicidal ideation or behaviour in patients on the smoking cessation drug.
Union wants in on pharmacy deal
Pharmacy employees' union Professional Pharmacists Australia wants the Prime Minister to intervene in 6CPA negotiations by inviting employed pharmacists and consumers to the table.
Top ten: Janssen closes in on Roche
PBS figures for August show that Janssen is closing on Roche and could soon take second place on the league table, meanwhile Novartis continues to dominate by a wide margin.
STA to file macular oedema insert
Now that pSivida has won FDA approval for micro-insert drug
for diabetic macular oedema, Specialised Therapeutics Australia plans to seek local registration.
New Chemmart each week: Symbion
Symbion's Chemmart banner is growing by one new pharmacy every week, the wholesaler has claimed.
Bayer wins Pharmac cash
Bayer has won further funding from New Zealand's Pharmac for its subdermal implant of contraceptive levonorgestrel, marketed as Jadelle, to 2017.
James calls for new govt agreement
One of the big ticket items on incoming Medicines Australia's chief Tim James' to-do list is to develop a 'framework' for industry, government and community to work together.
Astellas to expand Aust activities
Astellas has plans to transform into a much more 'prominent player' in the urological sector in Australia, starting with the retrieval of two drugs from licensee bioCSL.
Aust waits, EU takes new hep C step
As Australia continues an indefinite wait for PBS listing of the breakthrough hepatitis C treatment
, Europe is already moving to permit marketing of its successor drug.
Alexion bows on Soliris, still critical
Despite not accepting the PBAC's terms for listing of
, Alexion will supply the drug to treat aHUS sufferers.
Avastin + Xeloda a winner for Roche
New studies show that adding
boosts progression-free survival in women with HER2-negative metastatic breast cancer says Roche
How to save $70m on regulation
Complementary Medicines Australia says 'light touch' regulation could save its members $70 million a year and is telling the government how to go about it.
GSK, Monash join to save mothers
A life-saving treatment for mothers in developing countries pioneered at the Monash Institute of Pharmaceutical Sciences is to be developed by an international consortium of public and private bodies.
ASMI hoses down paracetamol fears
ASMI has warned against over-reaction to new research purporting to reinforce a link between mothers taking paracetamol during pregnancy and their children developing ADHD.
Billion dollar surge in PBS YTD
It seems the slowdown in PBS spending growth that emerged in July may have been just a breather with the latest numbers showing a significantly higher flow of dollars is continuing.
Budget bounce shows industry split
The final budget outcome for 2013-14 has exposed the expanding gulf between patented and generic medicine companies in Australia.
Vertex opens more CF otpions
Although its cystic fibrosis treatment
is yet to be PBS listed Vertex has secured it another orphan drug status in combination with experimental drug lumacaftor.
Sports stars push for Soliris listing
Ironman Guy Leech and world champion surfer Layne Beachley are among sporting celebrities campaigning for PBS listing of Alexion's aHUS drug
All evidence says PBS sustainable
One report after another confirms that the PBS is sustainable, and the latest AIHW study is no different, says Medicines Australia's Martin Cross.
OTC switches could save billions
Switching a dozen currently prescription-only medicines to OTC could save the community as much as $2.1 billion a year new research has shown.
Bisphosphonates for osteoarthritis
The use of bisphosphonates as a disease modifying agent in osteoarthritis will be investigated in a new NHMRC funded research study.
M&A confusion: have inversion deals gone sour?
Confused about where 2014's flurry of mergers and acquisitions stand and how they could affect you? In this update we analyse how changes to US tax regulations have made the inversion strategy less attractive and may threaten some key deals.
BMS ahead of the PD-1 oncology pack
BMS has announced EMA acceptance of its filing for PD-1 immune checkpoint inhibitor
while new cancer data flows in from the Euro Society for Medical Oncology meeting.
Aspen moves on glaucoma market
Aspen has registered new competition for MSD Australia's
, while Mundipharma has won approval for new doses of painkiller
Tim James' vision for Medicines Australia
Medicines Australia's new chief executive Tim James speaks to
Pharma in Focus
about how personal experience has shaped his view of industry where he believes he can make a difference.
When silence is leaden: the meaning of media avoidance
What do you think when a major corporate figure responds to the media with silence, declining to be interviewed? Is it signal of evasion, a conditioned response to regulatory curbs or just sensibly avoiding a hammering?
weighs the inferences.
Are you a slave to technology?
According to a recent survey conducted by Ipsos on behalf of Microsoft, 76 per cent of us use a smartphone and 45 per cent use a tablet. Does this mean technology is taking over our working and private lives?
Events & Conferences
© 2003 - 2014 Lush Media
Pharma in Focus
Jolly Good Design